Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Tuberculosis Diagnosis and Vaccines Research
share announcement

Tuberculosis Diagnosis and Vaccines Research

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines Against Tropical and Other Infectious Diseases".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 6276

Special Issue Editor

Dr. Shumaila Nida Javed Tunio

E-Mail Website
Guest Editor
Biomedical Sciences, Kentucky College of Osteopathic Medicine (KYCOM), University of Pikeville, Pikeville, KY, USA
Interests: developing new diagnostic methods; new drugs; new vaccines for tuberculosis

Special Issue Information

Dear Colleagues,

The Special Issue "Tuberculosis Diagnosis and Vaccines Research" aims to highlight the latest advancements in the detection and prevention of tuberculosis (TB), a significant global health threat. Despite ongoing efforts, TB remains one of the leading causes of death worldwide, exacerbated by the emergence of drug-resistant strains. This issue will focus on innovative diagnostic techniques, including molecular methods, imaging technologies, and biomarker discovery, which promise to enhance early detection and improve patient outcomes. Additionally, we invite contributions exploring novel vaccine candidates, immunological approaches, and the role of host-pathogen interactions in vaccine development. By fostering a multidisciplinary dialogue, this Special Issue seeks to bring together researchers, clinicians, and public health experts to share insights and propel the fight against TB. We encourage submissions that present cutting-edge bench research articles and Editorials, case studies, and review articles.

Dr. Shumaila Nida Javed Tunio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • developing new diagnostic methods
  • new drugs
  • new vaccines for tuberculosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 4886 KB  
Article
Rv2656c: A Potential Candidate Antigen Associated with Latent Tuberculosis Infection
by Yunjie Du, Pu He, Wenrui Dang, Ting Zhou, Yinjuan Song, Xiaoping Li, Yuhao Zhao, Fei Li, Aizhen Guo and Bingdong Zhu
Vaccines 2026, 14(5), 442; https://doi.org/10.3390/vaccines14050442 - 15 May 2026
Viewed by 141
Abstract
Background/Objectives: Several subunit vaccines for tuberculosis (TB), such as MVA85A and H4:IC31, have not demonstrated ideal protective efficacy in clinical trials, which may be attributed to their limited antigenic profile and lack of effective latency-associated antigens. In this study, we combined bioinformatics with [...] Read more.
Background/Objectives: Several subunit vaccines for tuberculosis (TB), such as MVA85A and H4:IC31, have not demonstrated ideal protective efficacy in clinical trials, which may be attributed to their limited antigenic profile and lack of effective latency-associated antigens. In this study, we combined bioinformatics with experimental validation to screen for latency-associated antigens that have immune-protective effects. Methods: Highly expressed antigens were identified from models related to latent infections, such as hypoxia and nutritional starvation. Their physicochemical properties and immunogenicity were predicted using online tools such as Expasy-ProParam, IEBD, and VaxiJen. The immunogenicity of these antigens was then evaluated in multiple mycobacterium infection models. Finally, a systematic evaluation of the immune response and protective effects induced by the candidate antigens was performed in a mouse model using intracellular cytokine detection, mycobacterium growth inhibition assays (MGIAs), antibody-dependent cellular phagocytosis (ADCP), and a latent tuberculosis infection (LTBI) mouse model. Results: The antigen Rv2656c is highly expressed in the nutritional starvation model and demonstrates strong immunogenicity in both infected humans and cattle. Moreover, Rv2656c exerted a significant inhibitory effect against Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium avium (M. avium) infections in MGIA. The humoral immune response elicited by Rv2656c enhanced the phagocytosis and killing of Mycobacteria by macrophages in vitro. Furthermore, in a mouse model of LTBI established using the attenuated M. tuberculosis H37Ra strain, treatment with Rv2656c significantly decreased the bacterial load in the lungs of the mice. Conclusions: Latency-associated Rv2656c may serve as an immune-protective antigen, offering potential for the development of novel multi-stage antigen subunit vaccine against TB. Full article
(This article belongs to the Special Issue Tuberculosis Diagnosis and Vaccines Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 1207 KB  
Review
Tuberculosis: Clinical Laboratory Diagnostic Techniques and Future Perspectives
by Qiuyue Song, Junlin Liu and Chunhua Wang
Vaccines 2026, 14(1), 38; https://doi.org/10.3390/vaccines14010038 - 29 Dec 2025
Viewed by 2247
Abstract
Tuberculosis is a severe infectious disease caused by Mycobacterium tuberculosis (MTB) infection and poses a serious public health challenge globally. The prevalence of multidrug-resistant MTB in countries with a high burden of tuberculosis has further increased the challenges of tuberculosis prevention and control. [...] Read more.
Tuberculosis is a severe infectious disease caused by Mycobacterium tuberculosis (MTB) infection and poses a serious public health challenge globally. The prevalence of multidrug-resistant MTB in countries with a high burden of tuberculosis has further increased the challenges of tuberculosis prevention and control. The rapid and accurate diagnosis of MTB and multidrug-resistant MTB serves as the prerequisite and key to controlling tuberculosis transmission and prevalence. However, the insufficient laboratory diagnosis capacity of tuberculosis seriously constrains the detection of tuberculosis cases, leading to delayed treatment and interpersonal transmission. Although multiple laboratory diagnostic techniques for tuberculosis have emerged, their diagnostic efficacy varies significantly. This review conducts a detailed analysis of the principles, characteristics, and clinical applications of various laboratory diagnostic techniques across three major categories: bacteriological morphology, molecular biology, and immunology. It elucidates the advantages and disadvantages of each technique and explores future development directions for tuberculosis laboratory diagnostics, aiming to provide valuable methodological references for the clinical diagnosis and treatment of tuberculosis. Full article
(This article belongs to the Special Issue Tuberculosis Diagnosis and Vaccines Research)
►▼ Show Figures

Figure 1

20 pages, 1242 KB  
Review
BCGitis and BCGosis: Clinical Spectrum, Immunological Mechanisms, and Risk Management
by Qibin Liu, Xiyong Dai and Shuang Wei
Vaccines 2025, 13(12), 1179; https://doi.org/10.3390/vaccines13121179 - 21 Nov 2025
Cited by 1 | Viewed by 3153
Abstract
Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB), administered to >100 million neonates annually. It confers approximately 70–80% protection against tuberculous meningitis and miliary TB in early childhood, under-pinning its continued use in high-burden settings. As a live-attenuated vaccine, however, [...] Read more.
Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB), administered to >100 million neonates annually. It confers approximately 70–80% protection against tuberculous meningitis and miliary TB in early childhood, under-pinning its continued use in high-burden settings. As a live-attenuated vaccine, however, BCG can rarely cause adverse reactions ranging from self-limited local lesions to life-threatening disseminated BCG disease (BCGosis), which almost exclusively occurs in infants with severe primary or acquired immunodeficiencies such as SCID, MSMD, CGD, or symptomatic HIV infection. Implementation of universal newborn screening for severe combined immunodeficiency (SCID) using the T-cell receptor excision circle (TREC) assay now enables prospective identification and deferral of these high-risk neonates, virtually eliminating fatal BCGosis. Here we synthesize global data published since 2010 on the clinical spectrum, immunopathogenesis, and epidemiology of BCG-related complications, highlighting the impact of vaccine substrain, administration technique, and host immune status on adverse-event rates. On the basis of this evidence, we propose a practical, evidence-based risk-assessment checklist (BCG-RAKE) to support safer vaccine deployment while preserving the substantial TB-control benefits of universal BCG immunization. Full article
(This article belongs to the Special Issue Tuberculosis Diagnosis and Vaccines Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop